WHO Establishes High-Level Commission On Noncommunicable Diseases 10/10/2017 by William New The UN World Health Organization today announced it has established a new high-level global commission on noncommunicable diseases, to be chaired by former WHO director general candidate Sania Nishtar of Pakistan. Continue reading -> WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 by William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> WHO Names New Leadership Team 03/10/2017 by William New The World Health Organization today announced the new leadership team for the UN agency, with a range of geographic representation and a majority of women in the top posts. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 by William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 by William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO […] Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient 05/10/2017 by William New At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR. Continue reading -> WHO Names New Leadership Team 03/10/2017 by William New The World Health Organization today announced the new leadership team for the UN agency, with a range of geographic representation and a majority of women in the top posts. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 by William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 by William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO […] Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
WHO Names New Leadership Team 03/10/2017 by William New The World Health Organization today announced the new leadership team for the UN agency, with a range of geographic representation and a majority of women in the top posts. Continue reading -> Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 by William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 by William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO […] Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest 25/09/2017 by William New NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 by William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO […] Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 by William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO […] Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 by William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
WIPO, IFPMA Speaker Says Despite Trump Actions, He Would Be US Science Envoy 24/08/2017 by William New A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 by William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 by William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts
The Case For Nations To Act On Medicines Access 23/07/2017 by William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> Posts navigation Older postsNewer posts